Q-omics provides the consensus-scored PGBP profile across patient tissues and cancer cell-line models. PGBP expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, PGBP is differentially expressed in 2, with the highest sampling consensus in KIRC. Additionally, PGBP RNA expression shows 6,362 significant pathway-activity associations, with the highest sampling consensus in KIRC. Together, these results highlight MESO, and KIRC as cancer lineages where PGBP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PGBP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PGBP survival associations across molecular data types. PGBP RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PGBP RNA expression–survival associations across cancer types. High PGBP expression shows unfavorable associations in MESO, UVM, LGG, ACC, CHOL and PAAD. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for PGBP RNA expression.
This table summarizes PGBP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for PGBP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PGBP shows lower tumor expression in ESCA and higher tumor expression in KIRC. The KIRC box plot shows higher PGBP RNA expression in tumor versus normal tissue (log2 FC = +0.033, t-test p < 0.001).
This table shows molecular features associated with PGBP in patient tissues and cancer cell lines. In patient samples, PGBP shows the broadest associations at the RNA and protein expression levels, with KIRC recurring as the lineage with the largest associated feature set.
